Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4459399 | 0.89 | KCNH2 (0.59) | KCNH2HDAC6SLC6A3EPHX2L3MBTL1 | |
| SCHEMBL4464147 | 0.89 | SLC6A3 (0.58) | HDAC6SMN1; SMN2SLC6A3EPHX2HDAC3 | |
| SCHEMBL4461322 | 0.87 | KCNH2 (0.58) | KCNH2HDAC6SLC6A3EPHX2L3MBTL1 | |
| SCHEMBL4465526 | 0.87 | KCNH2 (0.58) | KCNH2HDAC6SLC6A3EPHX2L3MBTL1 | |
| SCHEMBL4461324 | 0.87 | KCNH2 (0.58) | KCNH2HDAC6SLC6A3EPHX2L3MBTL1 | |
| SCHEMBL4475315 | 0.84 | SLC6A3 (0.60) | KCNH2HDAC6SLC6A3EPHX2 | |
| SCHEMBL4475302 | 0.82 | EPHX2 (0.53) | KCNH2HDAC6SLC6A3EPHX2 | |
| SCHEMBL5024621 | 0.81 | KCNH2 (0.73) | KCNH2MAPTSLC6A3 | |
| SCHEMBL13932375 | 0.80 | KCNH2 (0.64) | KCNH2HDAC6SLC6A3 | |
| SCHEMBL4462497 | 0.78 | EPHX2 (0.49) | KCNH2HDAC6SLC6A3EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511077-B2 | Diamine calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-03-31 | — | — | US | claimed |
| US-20060235050-A1 | Diamine calcium channel blockers | NUEROMED TECHNOLOGIES, INC. (CA) | 2006-10-19 | — | — | US | claimed |
| US-7511077-B2 | Diamine calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-03-31 | — | — | US | disclosed |
| US-7511077-B2 | Diamine calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-03-31 | — | — | US | disclosed |
| US-7511077-B2 | Diamine calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-03-31 | — | — | US | disclosed |
| US-20060235050-A1 | Diamine calcium channel blockers | NUEROMED TECHNOLOGIES, INC. (CA) | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235050-A1 | Diamine calcium channel blockers | CACNA1G, CACNA1H, CACNA1I | KCNH2 44/4885HDAC6 2931/4885MEN1 2601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.